Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous...

Summit Therapeutics表示Ivonescimab數據已在2024年ESMO年會上進行了展示，包括兩個報告和一份海報，其中包含了愛文思控股在晚期三陰性乳腺癌、復發/轉移性頭頸鱗狀細胞癌中的更新Ivonescimab數據。

Benzinga · 09/16 18:32

Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma, And Metastatic Microsatellite-stable Colorectal Cancer

Summit Therapeutics表示，愛文思控股的伊沃尼西麥數據已在2024年ESMO年會上發表，包括兩次展示和一篇海報，介紹了愛文思控股在愛文思控股在愛文思控股在愛文思控股在愛文思控股在愛文思控股的高級三陰性乳腺癌、復發/轉移性頭頸鱗狀細胞癌和轉移性微衛星穩定結直腸癌中的更新數據。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。